Exclusive Summary

• Midazolam nasal spray, as an FDA-approved innovative dosage form, offers significant clinical advantages and market potential for rapid out-of-hospital administration in specific acute conditions (e.g., status epilepticus, acute anxiety).
• The originator patent has expired, and market competition is still in its early stages, particularly in pediatric and specific adult indications, presenting opportunities for differentiated competition.
• US-FDA GMP certification and USP pharmacopeial standards ensure the product's leading international quality and significant advantages in global market access, providing a solid foundation for overseas collaborations.
• Compared to intravenous injection or oral formulations, the nasal spray offers non-invasive, rapid onset, and ease of use, addressing unmet medical needs in emergency scenarios.
• In the vast global market for epileptic emergency treatment and anxiety disorders, midazolam nasal spray, with its unique drug delivery route and efficacy, is expected to rapidly capture market share and gain guideline recommendations.